A new type of eye drug matched standard anti-VEGF therapy in a large trial for diabetic macular edema, a disease affecting 1.6 million Americans.
News|Articles|March 17, 2025
Retraction: Water-Free Topical Cyclosporine Improved Dryness Score in Dry Eye
Author(s)Julia Bonavitacola
Listen
0:00 / 0:00
Key Takeaways
- The study on topical cyclosporine contained calculation errors affecting its conclusions.
- Authors requested a temporary retraction to review and correct inaccuracies.
Advertisement
The American Journal of Managed Care has been informed that this previous study held several inaccuracies regarding topical cyclosporine, including calculation errors that could have affected the study's conclusions.
At the request of the authors, we are temporarily retracting the news article until inaccuracies in the data published are reviewed and corrected.
Advertisement
Related to this article
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.
Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.
The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
Longer undetectable hepatitis D RNA on bulevirtide predicts durable suppression off therapy, but rebound and ALT flares rise, especially in cirrhosis.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Access and Innovation in North Carolina’s Research Triangle
3
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
4
An Odyssey of Symptoms, Setbacks, Treatments, and a Cure With CAR T-Cell Therapy
5